 Shelley Miyamoto
Concepts (388)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Transplantation | 39 | 2025 | 736 | 4.950 |
Why?
| | Heart Defects, Congenital | 16 | 2025 | 914 | 2.890 |
Why?
| | Heart Failure | 19 | 2025 | 2329 | 2.420 |
Why?
| | Cardiomyopathy, Dilated | 14 | 2025 | 359 | 2.380 |
Why?
| | Heart Ventricles | 15 | 2022 | 760 | 2.280 |
Why?
| | MicroRNAs | 9 | 2025 | 701 | 1.850 |
Why?
| | Heart-Lung Transplantation | 2 | 2025 | 13 | 1.840 |
Why?
| | Circulating MicroRNA | 3 | 2023 | 26 | 1.520 |
Why?
| | Cardiomyopathies | 7 | 2023 | 338 | 1.480 |
Why?
| | Disease Management | 4 | 2025 | 647 | 1.470 |
Why?
| | Lung Transplantation | 2 | 2025 | 338 | 1.420 |
Why?
| | Myocardium | 8 | 2021 | 939 | 1.380 |
Why?
| | Societies, Medical | 2 | 2025 | 888 | 1.330 |
Why?
| | Hypoplastic Left Heart Syndrome | 6 | 2017 | 120 | 1.290 |
Why?
| | Myocytes, Cardiac | 8 | 2025 | 556 | 1.240 |
Why?
| | Milrinone | 2 | 2021 | 26 | 1.130 |
Why?
| | Ventricular Remodeling | 4 | 2021 | 276 | 1.090 |
Why?
| | Child | 66 | 2025 | 22657 | 1.040 |
Why?
| | Graft Rejection | 9 | 2025 | 540 | 1.000 |
Why?
| | Cardiomyopathy, Hypertrophic | 3 | 2023 | 145 | 0.910 |
Why?
| | Ventricular Function, Right | 2 | 2018 | 297 | 0.900 |
Why?
| | Heart Diseases | 5 | 2023 | 350 | 0.880 |
Why?
| | Ventricular Function, Left | 6 | 2024 | 541 | 0.850 |
Why?
| | Graft Survival | 8 | 2025 | 526 | 0.720 |
Why?
| | Cardiology | 1 | 2025 | 356 | 0.710 |
Why?
| | Infant | 33 | 2025 | 10039 | 0.660 |
Why?
| | Child, Preschool | 40 | 2025 | 11799 | 0.640 |
Why?
| | Clinical Trials as Topic | 1 | 2025 | 1055 | 0.620 |
Why?
| | Receptors, Adrenergic, beta | 3 | 2016 | 61 | 0.620 |
Why?
| | Down-Regulation | 4 | 2025 | 627 | 0.610 |
Why?
| | Mucocutaneous Lymph Node Syndrome | 1 | 2020 | 91 | 0.600 |
Why?
| | Phosphodiesterase 3 Inhibitors | 2 | 2016 | 14 | 0.590 |
Why?
| | Practice Guidelines as Topic | 2 | 2025 | 1563 | 0.580 |
Why?
| | Fever | 1 | 2020 | 312 | 0.570 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2018 | 23 | 0.570 |
Why?
| | Humans | 88 | 2025 | 144981 | 0.530 |
Why?
| | Pediatrics | 2 | 2025 | 1115 | 0.520 |
Why?
| | Steroids | 2 | 2015 | 160 | 0.510 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 2017 | 150 | 0.490 |
Why?
| | Hemodynamics | 6 | 2015 | 1122 | 0.490 |
Why?
| | Histone Deacetylases | 1 | 2017 | 210 | 0.460 |
Why?
| | Fontan Procedure | 4 | 2023 | 191 | 0.460 |
Why?
| | Female | 64 | 2025 | 78387 | 0.450 |
Why?
| | Male | 59 | 2025 | 72416 | 0.450 |
Why?
| | Case-Control Studies | 9 | 2025 | 3609 | 0.420 |
Why?
| | Echocardiography | 6 | 2021 | 653 | 0.410 |
Why?
| | Immunosuppressive Agents | 5 | 2025 | 847 | 0.390 |
Why?
| | Biomarkers | 9 | 2021 | 4276 | 0.380 |
Why?
| | Receptors, Adrenergic, beta-2 | 1 | 2012 | 35 | 0.370 |
Why?
| | Adaptation, Physiological | 2 | 2017 | 570 | 0.370 |
Why?
| | Adolescent | 37 | 2025 | 22453 | 0.370 |
Why?
| | Waiting Lists | 2 | 2013 | 263 | 0.360 |
Why?
| | Cardiovascular Diseases | 2 | 2022 | 2175 | 0.360 |
Why?
| | Calcium-Binding Proteins | 3 | 2021 | 220 | 0.350 |
Why?
| | Animals, Newborn | 5 | 2021 | 902 | 0.340 |
Why?
| | Phosphoric Diester Hydrolases | 3 | 2016 | 53 | 0.340 |
Why?
| | Adrenergic alpha-2 Receptor Agonists | 3 | 2017 | 25 | 0.340 |
Why?
| | Recovery of Function | 2 | 2015 | 710 | 0.340 |
Why?
| | Dexmedetomidine | 3 | 2017 | 44 | 0.340 |
Why?
| | Gene Expression Regulation | 3 | 2016 | 2609 | 0.330 |
Why?
| | Age Factors | 10 | 2024 | 3335 | 0.330 |
Why?
| | Connexin 43 | 2 | 2025 | 36 | 0.310 |
Why?
| | Phenotype | 4 | 2023 | 3164 | 0.310 |
Why?
| | Primary Graft Dysfunction | 1 | 2009 | 35 | 0.290 |
Why?
| | Cardiolipins | 3 | 2021 | 82 | 0.290 |
Why?
| | Renal Insufficiency, Chronic | 3 | 2025 | 653 | 0.290 |
Why?
| | Reoviridae Infections | 1 | 2009 | 55 | 0.280 |
Why?
| | Granuloma, Plasma Cell | 1 | 2008 | 12 | 0.280 |
Why?
| | Rats, Sprague-Dawley | 5 | 2021 | 2540 | 0.280 |
Why?
| | Extracorporeal Membrane Oxygenation | 2 | 2010 | 383 | 0.270 |
Why?
| | Adenosine Monophosphate | 2 | 2021 | 86 | 0.270 |
Why?
| | Everolimus | 2 | 2025 | 111 | 0.270 |
Why?
| | Myocarditis | 1 | 2009 | 102 | 0.270 |
Why?
| | Prospective Studies | 11 | 2021 | 8000 | 0.270 |
Why?
| | American Heart Association | 3 | 2024 | 352 | 0.270 |
Why?
| | Retrospective Studies | 23 | 2024 | 17101 | 0.270 |
Why?
| | Mycophenolic Acid | 2 | 2025 | 120 | 0.260 |
Why?
| | Cardiac Catheterization | 4 | 2017 | 561 | 0.260 |
Why?
| | Signal Transduction | 3 | 2017 | 5233 | 0.260 |
Why?
| | Tacrolimus | 2 | 2025 | 196 | 0.250 |
Why?
| | Real-Time Polymerase Chain Reaction | 3 | 2017 | 341 | 0.250 |
Why?
| | Coronary Artery Disease | 4 | 2024 | 742 | 0.250 |
Why?
| | Ventricular Outflow Obstruction | 2 | 2022 | 40 | 0.250 |
Why?
| | Kidney Transplantation | 2 | 2023 | 704 | 0.250 |
Why?
| | Phosphorylation | 4 | 2021 | 1733 | 0.240 |
Why?
| | Treatment Outcome | 16 | 2025 | 11699 | 0.240 |
Why?
| | Calcium | 3 | 2021 | 1184 | 0.240 |
Why?
| | Databases, Factual | 5 | 2016 | 1486 | 0.240 |
Why?
| | Adenylyl Cyclases | 2 | 2016 | 60 | 0.220 |
Why?
| | Infant, Newborn | 10 | 2021 | 6433 | 0.220 |
Why?
| | Coronary Vessels | 2 | 2017 | 251 | 0.220 |
Why?
| | Fibrosis | 2 | 2017 | 548 | 0.210 |
Why?
| | Heart-Assist Devices | 4 | 2019 | 567 | 0.210 |
Why?
| | Glomerular Filtration Rate | 2 | 2024 | 760 | 0.200 |
Why?
| | Cardiomyopathy, Restrictive | 1 | 2023 | 11 | 0.200 |
Why?
| | Allografts | 1 | 2024 | 150 | 0.200 |
Why?
| | Heart | 3 | 2022 | 636 | 0.190 |
Why?
| | Pulmonary Artery | 1 | 2009 | 1134 | 0.190 |
Why?
| | Sarcomeres | 1 | 2023 | 98 | 0.190 |
Why?
| | Cyclic AMP | 2 | 2014 | 210 | 0.180 |
Why?
| | Fibroma | 1 | 2022 | 20 | 0.180 |
Why?
| | Data Accuracy | 1 | 2022 | 65 | 0.180 |
Why?
| | Ventricular Dysfunction, Left | 3 | 2024 | 393 | 0.180 |
Why?
| | Heart Neoplasms | 1 | 2022 | 56 | 0.180 |
Why?
| | Barth Syndrome | 1 | 2021 | 9 | 0.180 |
Why?
| | Electron Transport Complex I | 1 | 2021 | 42 | 0.170 |
Why?
| | Focal Adhesions | 1 | 2021 | 47 | 0.170 |
Why?
| | Transcriptome | 2 | 2021 | 1046 | 0.170 |
Why?
| | Longevity | 1 | 2022 | 173 | 0.170 |
Why?
| | Fetofetal Transfusion | 1 | 2021 | 26 | 0.170 |
Why?
| | RNA-Binding Proteins | 1 | 2025 | 464 | 0.170 |
Why?
| | Cytokines | 1 | 2009 | 2065 | 0.170 |
Why?
| | Cells, Cultured | 4 | 2019 | 4155 | 0.160 |
Why?
| | Amniotic Fluid | 1 | 2021 | 79 | 0.160 |
Why?
| | Cardiac Output, Low | 1 | 2021 | 54 | 0.160 |
Why?
| | Cardiopulmonary Bypass | 3 | 2022 | 221 | 0.160 |
Why?
| | Probenecid | 1 | 2020 | 8 | 0.160 |
Why?
| | Calcium Channel Agonists | 1 | 2020 | 12 | 0.160 |
Why?
| | Serum | 2 | 2018 | 59 | 0.160 |
Why?
| | Heart Rate | 3 | 2023 | 855 | 0.160 |
Why?
| | Cardiotonic Agents | 1 | 2021 | 95 | 0.160 |
Why?
| | Predictive Value of Tests | 2 | 2024 | 2118 | 0.160 |
Why?
| | Isoproterenol | 2 | 2018 | 97 | 0.160 |
Why?
| | Apoptosis | 1 | 2009 | 2430 | 0.160 |
Why?
| | Young Adult | 13 | 2024 | 14126 | 0.160 |
Why?
| | Hypertension, Pulmonary | 3 | 2017 | 1980 | 0.150 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2020 | 126 | 0.150 |
Why?
| | ROC Curve | 3 | 2017 | 615 | 0.150 |
Why?
| | Time Factors | 7 | 2024 | 7184 | 0.150 |
Why?
| | Risk Factors | 11 | 2024 | 10797 | 0.150 |
Why?
| | Atrial Function, Right | 1 | 2019 | 14 | 0.150 |
Why?
| | Sarcoplasmic Reticulum Calcium-Transporting ATPases | 2 | 2021 | 33 | 0.150 |
Why?
| | Troponin I | 1 | 2019 | 72 | 0.150 |
Why?
| | Phosphodiesterase Inhibitors | 2 | 2016 | 73 | 0.140 |
Why?
| | Fatty Acids | 1 | 2021 | 452 | 0.140 |
Why?
| | Phosphodiesterase 5 Inhibitors | 1 | 2018 | 35 | 0.140 |
Why?
| | Tissue Donors | 3 | 2016 | 424 | 0.140 |
Why?
| | Mitochondria, Heart | 2 | 2020 | 102 | 0.140 |
Why?
| | Heart Atria | 1 | 2019 | 144 | 0.140 |
Why?
| | Lymphoproliferative Disorders | 2 | 2025 | 57 | 0.140 |
Why?
| | Surgical Wound Dehiscence | 1 | 2017 | 19 | 0.130 |
Why?
| | Rats | 5 | 2025 | 5614 | 0.130 |
Why?
| | Gene Regulatory Networks | 1 | 2020 | 320 | 0.130 |
Why?
| | Kidney Failure, Chronic | 1 | 2023 | 598 | 0.130 |
Why?
| | Protein Kinase C beta | 1 | 2017 | 21 | 0.130 |
Why?
| | Receptors, Adrenergic, alpha-2 | 1 | 2017 | 11 | 0.130 |
Why?
| | Animals | 11 | 2025 | 38111 | 0.130 |
Why?
| | Extracellular Matrix | 1 | 2021 | 553 | 0.130 |
Why?
| | G-Protein-Coupled Receptor Kinase 2 | 1 | 2016 | 9 | 0.130 |
Why?
| | Tissue Inhibitor of Metalloproteinases | 1 | 2016 | 19 | 0.130 |
Why?
| | Survival Analysis | 4 | 2021 | 1386 | 0.130 |
Why?
| | Drug Administration Schedule | 2 | 2017 | 783 | 0.120 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2016 | 56 | 0.120 |
Why?
| | Galectin 3 | 1 | 2016 | 21 | 0.120 |
Why?
| | Kaplan-Meier Estimate | 3 | 2015 | 966 | 0.120 |
Why?
| | Genetic Markers | 1 | 2017 | 331 | 0.120 |
Why?
| | Vectorcardiography | 1 | 2016 | 4 | 0.120 |
Why?
| | Isoenzymes | 1 | 2017 | 299 | 0.120 |
Why?
| | Death, Sudden, Cardiac | 1 | 2018 | 230 | 0.120 |
Why?
| | Electrocardiography | 3 | 2015 | 663 | 0.120 |
Why?
| | Patient Transfer | 1 | 2019 | 206 | 0.120 |
Why?
| | Cytomegalovirus Infections | 2 | 2025 | 206 | 0.120 |
Why?
| | Research Design | 1 | 2022 | 1137 | 0.120 |
Why?
| | Self Care | 1 | 2019 | 389 | 0.120 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2017 | 269 | 0.120 |
Why?
| | Specimen Handling | 1 | 2018 | 186 | 0.120 |
Why?
| | Adult | 13 | 2024 | 40511 | 0.120 |
Why?
| | Vascular Resistance | 1 | 2017 | 367 | 0.120 |
Why?
| | Sirolimus | 1 | 2017 | 281 | 0.120 |
Why?
| | Transition to Adult Care | 1 | 2017 | 96 | 0.120 |
Why?
| | Plasma | 1 | 2018 | 225 | 0.120 |
Why?
| | Statistics as Topic | 1 | 2016 | 284 | 0.120 |
Why?
| | Vasoconstriction | 1 | 2017 | 217 | 0.120 |
Why?
| | Exosomes | 1 | 2017 | 104 | 0.120 |
Why?
| | Incidence | 3 | 2025 | 2883 | 0.110 |
Why?
| | Mutation | 3 | 2023 | 4099 | 0.110 |
Why?
| | Arrhythmias, Cardiac | 1 | 2018 | 361 | 0.110 |
Why?
| | Up-Regulation | 1 | 2018 | 852 | 0.110 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2018 | 557 | 0.110 |
Why?
| | Perioperative Care | 1 | 2017 | 231 | 0.110 |
Why?
| | Fibrin Fibrinogen Degradation Products | 2 | 2012 | 93 | 0.110 |
Why?
| | Follow-Up Studies | 7 | 2024 | 5417 | 0.110 |
Why?
| | DNA Copy Number Variations | 1 | 2015 | 183 | 0.110 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2015 | 91 | 0.110 |
Why?
| | Surgical Wound Infection | 1 | 2017 | 316 | 0.110 |
Why?
| | Exercise Test | 3 | 2023 | 634 | 0.110 |
Why?
| | Myocardial Contraction | 3 | 2024 | 298 | 0.100 |
Why?
| | Tachycardia, Ventricular | 1 | 2016 | 181 | 0.100 |
Why?
| | Ketamine | 1 | 2015 | 133 | 0.100 |
Why?
| | Hypoalbuminemia | 1 | 2014 | 28 | 0.100 |
Why?
| | Stroke Volume | 2 | 2016 | 652 | 0.100 |
Why?
| | Coronary Angiography | 1 | 2016 | 324 | 0.100 |
Why?
| | Gene Expression Profiling | 2 | 2021 | 1786 | 0.100 |
Why?
| | Adrenergic beta-1 Receptor Antagonists | 1 | 2013 | 9 | 0.100 |
Why?
| | Growth Disorders | 1 | 2014 | 86 | 0.100 |
Why?
| | Anthracyclines | 1 | 2013 | 47 | 0.100 |
Why?
| | Hypnotics and Sedatives | 1 | 2015 | 216 | 0.100 |
Why?
| | Patient Compliance | 1 | 2017 | 589 | 0.100 |
Why?
| | Prognosis | 4 | 2015 | 4294 | 0.100 |
Why?
| | Vascular Diseases | 1 | 2016 | 251 | 0.100 |
Why?
| | Organ Transplantation | 1 | 2016 | 248 | 0.100 |
Why?
| | Propensity Score | 1 | 2015 | 367 | 0.100 |
Why?
| | Fetal Heart | 1 | 2013 | 57 | 0.090 |
Why?
| | Myosin Heavy Chains | 1 | 2014 | 185 | 0.090 |
Why?
| | Interleukin-1 | 1 | 2016 | 961 | 0.090 |
Why?
| | Cerebral Arterial Diseases | 1 | 2012 | 49 | 0.090 |
Why?
| | Patient Education as Topic | 1 | 2017 | 780 | 0.090 |
Why?
| | Tissue and Organ Procurement | 1 | 2016 | 346 | 0.090 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2012 | 168 | 0.090 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2012 | 111 | 0.090 |
Why?
| | Heart Arrest | 1 | 2015 | 407 | 0.090 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2014 | 196 | 0.090 |
Why?
| | Drug Therapy, Combination | 2 | 2025 | 1048 | 0.090 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2014 | 248 | 0.080 |
Why?
| | Altitude | 2 | 2021 | 473 | 0.080 |
Why?
| | Blood Coagulation Disorders | 1 | 2012 | 189 | 0.080 |
Why?
| | Postoperative Complications | 5 | 2025 | 2920 | 0.080 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2010 | 72 | 0.080 |
Why?
| | Pulmonary Embolism | 1 | 2012 | 244 | 0.080 |
Why?
| | Fibrinolytic Agents | 1 | 2012 | 292 | 0.080 |
Why?
| | Mycoses | 1 | 2010 | 88 | 0.080 |
Why?
| | United States | 8 | 2024 | 16000 | 0.080 |
Why?
| | Patient Selection | 1 | 2014 | 720 | 0.080 |
Why?
| | Transplantation, Homologous | 3 | 2021 | 415 | 0.080 |
Why?
| | RNA | 1 | 2016 | 940 | 0.080 |
Why?
| | Transplantation Conditioning | 1 | 2010 | 186 | 0.070 |
Why?
| | Air Ambulances | 1 | 2010 | 58 | 0.070 |
Why?
| | Thrombophilia | 1 | 2009 | 88 | 0.070 |
Why?
| | Oxygen Consumption | 2 | 2023 | 724 | 0.070 |
Why?
| | Colorado | 6 | 2017 | 4564 | 0.070 |
Why?
| | Transcription, Genetic | 1 | 2015 | 1496 | 0.070 |
Why?
| | Travel | 1 | 2010 | 136 | 0.070 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2017 | 1416 | 0.070 |
Why?
| | Cohort Studies | 6 | 2015 | 5966 | 0.070 |
Why?
| | Mitral Valve Stenosis | 1 | 2008 | 20 | 0.070 |
Why?
| | Angioplasty, Balloon | 1 | 2009 | 94 | 0.070 |
Why?
| | RNA, Transfer, Glu | 1 | 2007 | 6 | 0.070 |
Why?
| | Cardiac Surgical Procedures | 2 | 2017 | 609 | 0.070 |
Why?
| | Cell Line | 2 | 2025 | 2882 | 0.070 |
Why?
| | Registries | 2 | 2014 | 2389 | 0.060 |
Why?
| | Reoperation | 3 | 2021 | 631 | 0.060 |
Why?
| | Multicenter Studies as Topic | 2 | 2023 | 406 | 0.060 |
Why?
| | RNA, Messenger | 3 | 2021 | 2832 | 0.060 |
Why?
| | Mitochondrial Diseases | 1 | 2007 | 93 | 0.060 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2025 | 2032 | 0.060 |
Why?
| | Oxidation-Reduction | 2 | 2021 | 1087 | 0.060 |
Why?
| | Stem Cells | 1 | 2010 | 627 | 0.060 |
Why?
| | Brain Ischemia | 1 | 2009 | 358 | 0.060 |
Why?
| | Pregnancy | 2 | 2021 | 7191 | 0.060 |
Why?
| | Stents | 1 | 2009 | 556 | 0.050 |
Why?
| | 3' Untranslated Regions | 1 | 2025 | 152 | 0.050 |
Why?
| | Longitudinal Studies | 2 | 2024 | 2946 | 0.050 |
Why?
| | Stroke | 1 | 2012 | 1259 | 0.050 |
Why?
| | Protein Isoforms | 1 | 2025 | 402 | 0.050 |
Why?
| | Echocardiography, Doppler | 1 | 2024 | 115 | 0.050 |
Why?
| | Area Under Curve | 1 | 2024 | 331 | 0.050 |
Why?
| | Polymerase Chain Reaction | 2 | 2017 | 1054 | 0.050 |
Why?
| | Risk | 2 | 2019 | 912 | 0.050 |
Why?
| | Blotting, Western | 2 | 2016 | 1187 | 0.050 |
Why?
| | Pilot Projects | 2 | 2019 | 1891 | 0.050 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2015 | 758 | 0.050 |
Why?
| | Severity of Illness Index | 3 | 2021 | 2925 | 0.040 |
Why?
| | Endopeptidase K | 1 | 2021 | 18 | 0.040 |
Why?
| | Middle Aged | 4 | 2016 | 35937 | 0.040 |
Why?
| | Ribonucleases | 1 | 2021 | 49 | 0.040 |
Why?
| | Light Coagulation | 1 | 2021 | 10 | 0.040 |
Why?
| | Acyltransferases | 1 | 2021 | 78 | 0.040 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 2022 | 96 | 0.040 |
Why?
| | Serum Response Factor | 1 | 2021 | 33 | 0.040 |
Why?
| | Genotype | 2 | 2017 | 1835 | 0.040 |
Why?
| | Fetoscopy | 1 | 2021 | 33 | 0.040 |
Why?
| | Sensitivity and Specificity | 2 | 2016 | 1991 | 0.040 |
Why?
| | Exercise Tolerance | 1 | 2023 | 283 | 0.040 |
Why?
| | Microscopy, Atomic Force | 1 | 2021 | 134 | 0.040 |
Why?
| | Biomechanical Phenomena | 1 | 2024 | 842 | 0.040 |
Why?
| | Gene Expression | 2 | 2017 | 1490 | 0.040 |
Why?
| | Palliative Care | 1 | 2009 | 1008 | 0.040 |
Why?
| | Multivariate Analysis | 2 | 2014 | 1540 | 0.040 |
Why?
| | TRPV Cation Channels | 1 | 2020 | 43 | 0.040 |
Why?
| | Drainage | 1 | 2021 | 185 | 0.040 |
Why?
| | Cluster Analysis | 1 | 2021 | 521 | 0.040 |
Why?
| | Logistic Models | 1 | 2024 | 2119 | 0.040 |
Why?
| | Recurrence | 2 | 2012 | 1135 | 0.040 |
Why?
| | Resource Allocation | 1 | 2019 | 53 | 0.040 |
Why?
| | Ultrasonography, Prenatal | 1 | 2021 | 294 | 0.040 |
Why?
| | Ventricular Function | 1 | 2019 | 57 | 0.040 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2017 | 2147 | 0.040 |
Why?
| | Flecainide | 1 | 2018 | 8 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2021 | 442 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2021 | 744 | 0.040 |
Why?
| | Treatment Failure | 2 | 2010 | 365 | 0.040 |
Why?
| | DNA, Mitochondrial | 1 | 2020 | 212 | 0.030 |
Why?
| | Risk Assessment | 3 | 2016 | 3677 | 0.030 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2021 | 460 | 0.030 |
Why?
| | Exercise Therapy | 1 | 2023 | 473 | 0.030 |
Why?
| | Guinea Pigs | 1 | 2018 | 159 | 0.030 |
Why?
| | Inflammation | 1 | 2009 | 2880 | 0.030 |
Why?
| | Chronic Disease | 1 | 2024 | 1813 | 0.030 |
Why?
| | Ryanodine Receptor Calcium Release Channel | 1 | 2018 | 72 | 0.030 |
Why?
| | Neoplasms | 1 | 2013 | 2884 | 0.030 |
Why?
| | Administration, Oral | 1 | 2020 | 848 | 0.030 |
Why?
| | Freezing | 1 | 2018 | 86 | 0.030 |
Why?
| | Anti-Arrhythmia Agents | 1 | 2018 | 143 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2025 | 2050 | 0.030 |
Why?
| | Atrial Natriuretic Factor | 1 | 2016 | 57 | 0.030 |
Why?
| | Adenoidectomy | 1 | 2017 | 81 | 0.030 |
Why?
| | Cell Size | 1 | 2017 | 92 | 0.030 |
Why?
| | Sampling Studies | 1 | 2016 | 99 | 0.030 |
Why?
| | Observer Variation | 1 | 2017 | 355 | 0.030 |
Why?
| | Renin-Angiotensin System | 1 | 2017 | 78 | 0.030 |
Why?
| | Homeostasis | 1 | 2020 | 640 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2023 | 1722 | 0.030 |
Why?
| | Brain Death | 1 | 2016 | 60 | 0.030 |
Why?
| | Sympathetic Nervous System | 1 | 2017 | 178 | 0.030 |
Why?
| | Autopsy | 1 | 2016 | 94 | 0.030 |
Why?
| | Kidney | 1 | 2023 | 1496 | 0.030 |
Why?
| | Tonsillectomy | 1 | 2017 | 105 | 0.030 |
Why?
| | Stem Cell Transplantation | 1 | 2017 | 191 | 0.030 |
Why?
| | Diastole | 1 | 2016 | 143 | 0.030 |
Why?
| | Systole | 1 | 2016 | 178 | 0.030 |
Why?
| | Carrier Proteins | 1 | 2019 | 737 | 0.030 |
Why?
| | Italy | 1 | 2015 | 114 | 0.030 |
Why?
| | Markov Chains | 1 | 2015 | 130 | 0.030 |
Why?
| | Disease Models, Animal | 2 | 2018 | 4569 | 0.030 |
Why?
| | DNA, Complementary | 1 | 2015 | 277 | 0.030 |
Why?
| | Cardiac Output | 1 | 2015 | 179 | 0.030 |
Why?
| | Reference Values | 1 | 2016 | 798 | 0.030 |
Why?
| | Orthopedic Procedures | 1 | 2017 | 243 | 0.030 |
Why?
| | Mitochondria | 1 | 2021 | 984 | 0.030 |
Why?
| | Action Potentials | 1 | 2018 | 507 | 0.030 |
Why?
| | Hot Temperature | 1 | 2018 | 407 | 0.030 |
Why?
| | Arterial Pressure | 1 | 2015 | 136 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2019 | 1096 | 0.030 |
Why?
| | Self-Management | 1 | 2017 | 201 | 0.030 |
Why?
| | Public Health | 1 | 2019 | 566 | 0.030 |
Why?
| | Exons | 1 | 2015 | 358 | 0.030 |
Why?
| | Cardiovascular Surgical Procedures | 1 | 2014 | 30 | 0.030 |
Why?
| | Linear Models | 1 | 2016 | 854 | 0.030 |
Why?
| | Drug Therapy | 1 | 2014 | 80 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2016 | 1311 | 0.030 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2017 | 276 | 0.030 |
Why?
| | Analgesics | 1 | 2015 | 231 | 0.020 |
Why?
| | Odds Ratio | 1 | 2016 | 1077 | 0.020 |
Why?
| | Pandemics | 1 | 2022 | 1695 | 0.020 |
Why?
| | Program Evaluation | 1 | 2017 | 949 | 0.020 |
Why?
| | Self Report | 1 | 2017 | 873 | 0.020 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2013 | 139 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 851 | 0.020 |
Why?
| | Transplant Recipients | 1 | 2014 | 180 | 0.020 |
Why?
| | Mitochondrial Proteins | 1 | 2014 | 263 | 0.020 |
Why?
| | Heart Function Tests | 1 | 2012 | 59 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2016 | 1496 | 0.020 |
Why?
| | Mice | 3 | 2015 | 18366 | 0.020 |
Why?
| | Nutritional Status | 1 | 2014 | 354 | 0.020 |
Why?
| | Exercise | 1 | 2023 | 2201 | 0.020 |
Why?
| | Mice, Inbred C3H | 1 | 2010 | 251 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2014 | 1325 | 0.020 |
Why?
| | France | 1 | 2010 | 40 | 0.020 |
Why?
| | Diagnostic Imaging | 1 | 2012 | 339 | 0.020 |
Why?
| | Body Weight | 1 | 2014 | 978 | 0.020 |
Why?
| | Shock, Cardiogenic | 1 | 2010 | 64 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2010 | 529 | 0.020 |
Why?
| | Bone Marrow Transplantation | 1 | 2010 | 294 | 0.020 |
Why?
| | Adaptive Immunity | 1 | 2010 | 169 | 0.020 |
Why?
| | Bone Marrow Cells | 1 | 2010 | 320 | 0.020 |
Why?
| | Internationality | 1 | 2010 | 156 | 0.020 |
Why?
| | Factor VIII | 1 | 2009 | 104 | 0.020 |
Why?
| | Tricuspid Atresia | 1 | 2008 | 4 | 0.020 |
Why?
| | Venae Cavae | 1 | 2008 | 7 | 0.020 |
Why?
| | Survival Rate | 1 | 2014 | 2092 | 0.020 |
Why?
| | Mass Screening | 1 | 2017 | 1348 | 0.020 |
Why?
| | Vena Cava, Superior | 1 | 2008 | 25 | 0.020 |
Why?
| | Biopsy | 1 | 2012 | 1077 | 0.020 |
Why?
| | Device Removal | 1 | 2009 | 143 | 0.020 |
Why?
| | Age of Onset | 1 | 2009 | 551 | 0.020 |
Why?
| | Anastomosis, Surgical | 1 | 2008 | 157 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2010 | 1253 | 0.020 |
Why?
| | Probability | 1 | 2008 | 312 | 0.020 |
Why?
| | C-Reactive Protein | 1 | 2009 | 417 | 0.020 |
Why?
| | Anticoagulants | 1 | 2012 | 725 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2015 | 3416 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2007 | 307 | 0.020 |
Why?
| | Pulmonary Circulation | 1 | 2008 | 430 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2008 | 1268 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2017 | 6055 | 0.010 |
Why?
| | Aged | 2 | 2014 | 25957 | 0.010 |
Why?
| | Length of Stay | 1 | 2008 | 1337 | 0.010 |
Why?
| | T-Lymphocytes | 1 | 2010 | 1982 | 0.010 |
Why?
|
|
Miyamoto's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|